We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App





Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 21 Jun 2021
Print article
Image: Sofia Q Fluorescent Immunoassay Analyzer (Photo courtesy of Quidel Corporation)
Image: Sofia Q Fluorescent Immunoassay Analyzer (Photo courtesy of Quidel Corporation)
Quidel Corporation (San Diego, CA, USA) showcased its comprehensive suite of COVID-19 testing solutions at MEDLAB Middle East 2021 that took place in Dubai from 21-24 June.

Quidel introduced its new Sofia Q Fluorescent Immunoassay Analyzer, a powerful clinical diagnostic device in a very compact size, to be used with its Sofia SARS Antigen FIA Test Cassettes to diagnose COVID-19. Sofia Q uses advanced fluorescence detection with an ultraviolet LED energy source and collects hundreds of data points on the test strip contained inside the Test Cassette. Quidel recently received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition to the Sofia and Sofia 2 line of Fluorescent Immunoassay Analyzers (FIA).

In addition to the Sofia Q, Quidel also exhibited other rapid diagnostic instrumented systems, including Sofia 2, and Sofia. Also on display were Quidel’s Sofia assays for rapid antigen COVID-19 diagnosis, including Sofia 2 SARS Antigen FIA and Sofia 2 Flu + SARS Antigen FIA, currently under EUA by the FDA. At MEDLAB Middle East 2021, Quidel also highlighted its other FDA-cleared and CLIA-waived tests, including Influenza A and B, Respiratory Syncytial Virus (RSV), Group A Strep, and a 15-minute finger-stick whole blood test for Lyme Disease.

Related Links:
Quidel Corporation

Gold Member
Syphilis Screening Test
VDRL Antigen MR
New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Chemiluminescence Immunoassay Analyzer
AutoLumo A6200/A6600
New
H-FABP Test
Finecare H-FABP Rapid Quantitative Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Three newly identified protein biomarkers have the potential to improve diagnostic tools for colorectal cancer (Photo courtesy of Adobe Stock)

New Protein Biomarkers to Improve Diagnostic Tools for Colorectal Cancer

Colorectal cancer is a leading cause of cancer-related deaths globally, and its incidence is expected to rise in the coming decades. This cancer begins when abnormal cells grow uncontrollably in the large... Read more

Microbiology

view channel
Image: The CRISPR-TB Blood Test provides accurate, rapid, and cost-effective diagnosis (Photo courtesy of 123RF)

CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening

Tuberculosis (TB) continues to be a leading cause of global mortality, with 10.6 million new cases and 1.6 million deaths annually. Diagnosing TB remains difficult, with smear microscopy offering only... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.